Ethics and the Pharmaceutical Industry / Edition 1

Ethics and the Pharmaceutical Industry / Edition 1

by Michael A. Santoro, Thomas M. Gorrie

These papers by doctors, scholars, industry executives, and NGO representatives debate ethics in the pharmaceutical industry.See more details below


These papers by doctors, scholars, industry executives, and NGO representatives debate ethics in the pharmaceutical industry.

Product Details

Cambridge University Press
Publication date:
Edition description:
New Edition
Sales rank:
Product dimensions:
5.98(w) x 8.98(h) x 1.18(d)

Related Subjects

Meet the Author

Michael A. Santoro is Associate Professor with tenure in the Business Environment Department at Rutgers Business School, where he teaches courses on business ethics, public policy, labor and human rights, law, ethical issues in the pharmaceutical industry, and China business strategy. Professor Santoro holds a Ph.D. in Public Policy from Harvard University and a J.D. from the New York University School of Law. As a Research Associate at Harvard Business School, he wrote or co-authored nearly 30 case studies and teaching notes on ethical and legal topics such as global protection of intellectual property, insider trading, the Federal Sentencing Guidelines, and the Fair Credit Reporting Act. Professor Santoro has also published numerous journal articles, op-ed articles, and book chapters on these topics in publications such as Foreign Policy, and Human Rights Quarterly. He is the author of Profits and Principles: Global Capitalism and Human Rights in China (2000).

Thomas M. Gorrie is Corporate Vice President, Government Affairs & Policy at Johnson & Johnson, with responsibility as Corporate Officer for all federal, state, and international government affairs and policy. He has over 30 years of worldwide health care experience. He has worked with various Johnson & Johnson companies in research and development, marketing and sales, business development, strategic planning, general management, international venture capital, and health policy. Dr Gorrie received his Ph.D. in chemistry from Princeton University. He completed post-doctoral studies at the Swiss Federal Institute of Technology in Zurich. He serves on numerous non-profit boards, including Duke University Health Care System, Robert Wood Johnson University Hospital, the Dean's Advisory Board of the Rutgers Business School, and the Hun School of Princeton.

Read More

Table of Contents

Introduction : charting a sustainable path for the twenty-first century pharmaceutical industry1
Pt. IProfits, patients' rights, and scientific progress : the ethics of clinical research conducted in private enterprises
Introduction to part I9
1Drug research : between ethical demands and economic constraints21
2Emerging international norms for clinical testing : good clinical trial practice37
3The regulatory and ethical challenges of pediatric research48
4Including children in research : participation or exploitation?68
5Racial and ethnic inclusiveness in clinical trials80
6The rights of patients to participate in clinical research97
7How should government regulate stem-cell research? : views from a scientist-legislator109
Pt. IIMarketing and the efficient utilization of healthcare resources : ethical and public policy challenges
Introduction to part II127
8Ethics and prescribing : the clinician's perspective136
9The regulation of prescription drug promotion153
10Direct-to-consumer advertising of prescription drugs : a policy dilemma169
11Off-lable communications and prescription drugs184
12The need for better health information : advancing the informed patient in Europe196
13Who should get access to which drugs? An ethical template for pharmacy benefits206
14The application of cost-effectiveness and cost-benefit analysis to pharmaceuticals225
Pt. IIIPatents, pricing, and equal access
Introduction to part III251
15Intellectual property rights, access to life-enhancing drugs, and corporate moral responsibilities260
16A future agenda for government-industry relations282
17AIDS activism and the pharmaceutical industry300
18The campaign against innovation326
19Third world perspectives on global pharmaceutical access336
20The promise of vaccines and the influenza vaccine shortage of 2004 : public and private partnerships352
Pt. IVConcluding thoughts : charting a sustainable path for the twenty-first century
Introduction to part IV363
21Evolving approaches to healthcare challenges369
22Property rights in crisis : managers and rescue379
23Blurring the lines : public and private partnerships addressing global health386
24Renegotiating the grand bargain : balancing prices, profits, people, and principles393

Read More

Customer Reviews

Average Review:

Write a Review

and post it to your social network


Most Helpful Customer Reviews

See all customer reviews >